Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

SAN DIEGO, February 8, 2013 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG), today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US. [i]  

"People affected by EB suffer skin blisters and almost constant, acute pain and scarring," said the study's Principal Investigator, H. Alan Arbuckle , MD, Section Head Pediatric Dermatology Kaiser Permanente Colorado, Wound Care Consultant, Epidermolysis Bullosa Center of Excellence, The Children's Hospital, Aurora Colorado . "The current standard of care is daily wound care, bandaging and pain management. I am excited to be involved in testing the efficacy and safety of ABH001 as a potential treatment option for these patients."  

ABH001 for EB has been granted an orphan drug designation in the US and EU, and has also received Fast Track designation from the US Food and Drug Administration (FDA), which is aimed at facilitating the development and expediting the review of drugs and biologics that fill an unmet medical need. In addition, the European Medicines Agency's Pediatric Committee has agreed on a pediatric investigation plan for ABH001 for the treatment of EB.

The new Phase 3 study is a multi-site, prospective, randomized, open-label, intra-subject controlled trial evaluating the efficacy and safety of ABH001 to initiate healing and reduce the wound surface area of selected stalled, chronic cutaneous wounds associated with generalized EB. Approximately 20 subjects with generalized EB age
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
11. ODT Forum Presents Regenerative Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 2013 was a banner year ... Technologies®. They saw continued independent research led by the ... awarded a $1 million grant from the Susanne Marcus ... Behavior” a peer reviewed journal, Amy Grant highlighted Brainwave ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
(Date:1/14/2014)... 14, 2014 The largest international professional organization ... and therapeutic derivatives thereof has endorsed an educational ... about the challenges of adulterated herb and botanical ... The Society for Medicinal Plant and ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... 1 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix") (TSX:RVX) is pleased ... on May 8, 2008 at 9:00 pm MDT ... and the business aspects of the Company. Following ... answer session., The webcast can be accessed ...
... - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ... today announced that it has received 510(k),clearance from ... begin,marketing sizes 3-0 and 4-0 of its Quill ... SRS PDO is a longer-lasting,absorbable suture, which is ...
... SOUTH SAN FRANCISCO, Calif., May 1 Renovis,Inc. (Nasdaq: ... the,adoption of the merger agreement with Evotec AG (Frankfurt ... today. The merger is,expected to close by May 5, ... share of Renovis common,stock will be automatically converted into ...
Cached Biology Technology:Resverlogix Notice of Conference Call & Webcast 2Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO 2Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO 3Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO 4Renovis Stockholders Approve Acquisition by Evotec 2
(Date:4/23/2014)... greater prevalence of asthma, allergies and other chronic inflammatory ... due in part to their reduced exposure to the ... new scientific paper. , The article, published in the ... people living in urban centers who have less access ... chronic inflammation, a condition caused by immune system dysfunction. ...
(Date:4/23/2014)... with Huntington,s disease, most in their mid-thirties and ... and behavioral decline within two decades. "Mutant" protein ... genetic disease, have been the primary focus of ... to new research from Prof. Gerardo Lederkremer and ... of Cell Research and Immunology, in collaboration with ...
(Date:4/23/2014)... 23, 2014) People who have had a stroke, ... neurological function. However, a study conducted in Taiwan, that ... Cell Transplantation , but is currently freely available on-line ... has found that when one group of stroke victims ... directly into the brain and a similar group did ...
Breaking Biology News(10 mins):Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3On the defensive 2On the defensive 3Autologous stem cell therapy improves motor function in chronic stroke victims 2
... University of Leicester and part-funded by The Leverhulme Trust aims ... By bringing together an artist and a neuroscientist, both ... perception. In the process of the research, both artist and ... the eye of the beholder. Rodrigo Quian Quiroga, Neuroscientist ...
... opinion that inflammation in adipose tissue may cause insulin resistance, ... Swedish medical university Karolinska Institutet, published in the New ... in the body fat is only pernicious. Instead the findings ... necessary for fat cell turnover in the lean, healthy state. ...
... not just thinking big but also very, very, very ... director of Binghamton University,s Center for Advanced Sensors and ... that would detect and identify engineered nanoparticles. Her research ... the environmental release and transformation of these particles. ...
Cached Biology News:Beauty is in the eye of the beholder? 2Inflammation in body fat is not only pernicious 2Chemist monitors nanotechnology's environmental impact 2
A univariate (peak height or area) quantitative multi-component analysis package....
... The micro 1 is a dramatic breakthrough ... from 1mL with 10nL resolution, the micro 1 ... benchtop dispenser. And, the micro 1 never needs ... , Touch Screen programming on an LCD Display ...
... microscopes offer all of the features of ... Equipped with Koehler illumination, a centerable condenser ... B3 is the workhorse of Motic's range ... the need for re-focusing following a change ...
... Dye Primer Manual Cycle Sequencing Kit is ... primers and high-resolution fluorescence scanners. Sequencing reactions ... slab gel electrophoresis and scanning of the ... The kit components have been optimized ...
Biology Products: